Cited 8 times in
Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.contributor.author | 이금화 | - |
dc.date.accessioned | 2020-02-11T06:31:02Z | - |
dc.date.available | 2020-02-11T06:31:02Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174709 | - |
dc.description.abstract | We conducted a systematic review for evidence of the clinical efficacy of cancer immunotherapies. We searched PubMed from inception to 14 February 2018 for meta-analyses of randomized controlled trials (RCTs) of cancer immunotherapies. Re-analyses were performed to estimate the summary effect size under random-effects, the 95% confidence interval (CI), heterogeneity, and the 95% prediction interval, and we determined the strength of the evidence. We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma, adoptive cell immunotherapy for NSCLC, and the combination of interferon α and chemotherapy for metastatic melanoma. A further meta-analysis of 16 RCTs showed that anti-PD-1/PD-L1 mAb therapy had a benefit in patients with solid tumors (overall survival; hazard ratio = 0.73, 95% CI: 0.68-0.79; p < 0.001), supported by convincing evidence. In the future, rigorous approaches are needed when interpreting meta-analyses to gain better insight into the true efficacy of cancer immunotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아청소년과학교실) | - |
dc.contributor.googleauthor | Jong Yeob Kim | - |
dc.contributor.googleauthor | Keum Hwa Lee | - |
dc.contributor.googleauthor | Michael Eisenhut | - |
dc.contributor.googleauthor | Hans J. van der Vliet | - |
dc.contributor.googleauthor | Andreas Kronbichler | - |
dc.contributor.googleauthor | Gwang Hun Jeong | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.contributor.googleauthor | Gabriele Gamerith | - |
dc.identifier.doi | 10.3390/cancers11111801 | - |
dc.contributor.localId | A02142 | - |
dc.contributor.localId | A04622 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 31731818 | - |
dc.subject.keyword | cancer | - |
dc.subject.keyword | immunotherapy | - |
dc.subject.keyword | meta-analysis | - |
dc.subject.keyword | umbrella review | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | 신재일 | - |
dc.contributor.affiliatedAuthor | 이금화 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | E1801 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.11(11) : E1801, 2019 | - |
dc.identifier.rimsid | 63567 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.